<DOC>
	<DOCNO>NCT01421342</DOCNO>
	<brief_summary>The overall purpose determine research base 'next-steps ' outpatient major depressive disorder satisfactory outcomes standard 'first-step ' treatment . The primary objective compare acute ( 12 week ) treatment effectiveness augment antidepressant aripiprazole bupropion-SR vs. switch treatment bupropion-SR monotherapy symptom remission Veterans Major Depressive Disorder ( MDD ) achieve optimal response adequate trial antidepressant ( SSRI SNRI mirtazapine ) monotherapy . The secondary objective compare acute ( 12 week ) long term ( 36 week ) efficacy , safety , effect function , suicidality , quality life , anxiety associate symptom , cost cost-effectiveness three treatment .</brief_summary>
	<brief_title>VA Augmentation Switching Treatments Improving Depression Outcomes</brief_title>
	<detailed_description>The overall aim VAST-D enhance treatment outcomes representative outpatient diagnose nonpsychotic major depressive disorder ( MDD ) treat primary psychiatric VA care setting . In particular , VAST-D design determine comparative effectiveness different treatment option participant MDD fail satisfactory outcome treatment initial antidepressant . These option may conceptualize represent two overall treatment strategy : 1 ) Medication Switch - switch initial antidepressant another antidepressant medication , specifically bupropion-SR 2 ) Medication Augmentation - augment initial antidepressant second antidepressant , specifically bupropion-SR second generation antipsychotic , specifically aripiprazole . VAST-D 's primary goal determine 3 treatment strategy likely lead remission . Other key objective include comparison response , time remission , time response , relapse , anxiety symptom , suicidal ideation behavior , side effect , tolerability , quality life , health related cost satisfaction participation study . VAST-D enroll 1518 total patient gender ethnic/racial socioeconomic background . All patient meet DSM-IV-TR criterion nonpsychotic MDD . The diagnostic criterion eligibility establish clinical interview supplement 9-item Patient Health Questionnaire ( PHQ-9 ) . Final determination eligibility make study clinician . Only participants suboptimal outcome well document , adequately deliver ( dose duration ) , trial selective serotonin reuptake inhibitor ( SSRI ) serotonin norepinephrine reuptake inhibitor ( SNRI ) mirtazapine eligible study . Failure achieve adequate outcome ascertain QIDS-C16 &gt; = 16 ( consider severe depression ) least 6 week treatment &gt; = 11 ( consider moderately severe depression ) least 8 week treatment . Otherwise , inclusion criterion broad exclusion criterion ; participant comorbid general medical psychiatric disorder generally include provide broadly representative sample . Participants randomize ( 1:1:1 ratio ) switch bupropion-SR alone ( n=506 ) , current antidepressant plus bupropion-SR ( n=506 ) , current antidepressant plus aripiprazole ( n=506 ) . Treatment guide clinician-rated symptom measure ( PHQ-9 ) global side effect measure ( Frequency , Intensity , Burden Side Effects Rating FIBSER ) obtain treatment visit . Acute treatment visit occur baseline week 1 , 2 , 4 , 6 , 8 , 10 , 12 ensure delivery appropriate yet vigorous tolerable pharmacotherapy . Participants tolerate acute treatment achieve adequate response 12 week enter 24-week Continuation Treatment phase , initial treatment continue visit occur every four week subsequently patient follow 36 week post-randomization . The QIDS-C16 administered baseline follow-up visit independent evaluator ( blind treatment assignment ) measure symptoms depression study outcomes remission , response relapse . Neither participant treating clinician blind treatment . Primary hypothesis : Primary hypothesis 1.a : Remission rate major depressive disorder high patient whose treatment augment bupropion-SR ( antidepressant + bupropion-SR ) compare switch bupropion-SR monotherapy . Primary Hypothesis 1.b : Remission rate major depressive disorder high patient whose treatment augment aripiprazole ( antidepressant + aripiprazole ) compare switch bupropion-SR monotherapy . Secondary hypothesis : Secondary Hypothesis 2.a : Remission rate great patient whose treatment augment bupropion-SR ( antidepressant + bupropion-SR ) augment aripiprazole ( antidepressant + aripiprazole ) . Secondary Hypothesis 2.b : Relapse rate ( within 36 week initiation treatment ) low patient whose antidepressant augment bupropion-SR ( antidepressant + bupropion-SR ) whose antidepressant switch bupropion-SR monotherapy . Secondary Hypothesis 2.c : Relapse rate ( within 36 week initiation treatment ) low patient whose treatment augment aripiprazole ( antidepressant + aripiprazole ) vs. switch bupropion-SR monotherapy . Secondary Hypothesis 2.d : Relapse rate ( within 36 week initiation treatment ) low patient whose treatment augment bupropion-SR ( antidepressant + bupropion-SR ) patient whose treatment augment aripiprazole ( antidepressant + aripiprazole ) . Secondary Hypothesis 2.e : The proportion patient develop akathisia , akathisia-like side effect ( e.g. , tremor , irritability , motor restlessness ) extrapyramidal side effect great patient whose antidepressant treatment augment aripiprazole ( antidepressant + aripiprazole ) compare patient whose treatment augment bupropion-SR ( antidepressant + bupropion-SR ) , switch bupropion-SR monotherapy . Secondary Hypothesis 2.f : The relative cost ( direct indirect ) augment antidepressant aripiprazole ( antidepressant + aripiprazole ) great cost antidepressant augmentation bupropion-SR ( antidepressant + bupropion-SR ) , cost antidepressant augmentation bupropion-SR ( antidepressant + bupropion-SR ) great cost switch bupropion-SR monotherapy , augmentation monotherapy bupropion-SR cost-effective aripiprazole augmentation .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>DSMIV diagnosis single recurrent , nonpsychotic , major depressive disorder Currently take selective serotonin reuptake inhibitor ( SSRI ) serotoninnorepinephrine reuptake inhibitor ( SNRI ) mirtazapine major depressive disorder Need `` nextstep '' treatment base document suboptimal outcome current antidepressant treatment major depressive episode ( least 6 week treatment QIDSC16 &gt; = 16 least 8 week QIDSC16 &gt; = 11 ; least 3 week stable `` optimal '' dose Age : 18 year age old Prior inadequate response adequate treatment trial clear cut intolerance either study medication ( aripiprazole bupropion ) Current treatment bupropion , aripiprazole antipsychotic agent Lifetime history bipolar disorder , schizophrenia , schizoaffective disorder , psychosis otherwise specify Current diagnosis Dementia Current diagnosis eat disorder seizure disorder High suicide risk currently require acute intervention ( outpatient treatment depression ) Unstable , serious medical condition one require acute medical treatment , anticipation hospitalization extend care Requiring immediate hospitalization psychiatric disorder Physiologic substance dependence require detoxification ( exclude nicotine ) past 30 day ( substance abuse exclusion criterion ) Taking concomitant medication contraindicates treatment option augment agent know antidepressant effect Concurrent recent participation ( within last 30 day ) another conflict clinical trial mental health , investigational drug , medical device intervention Female pregnant lactate plan become pregnant Patient able willing provide inform consent ; change mind participate prior randomization Patient refer study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Mood Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Depressive Disorder</keyword>
	<keyword>Depressive Disorder , Major</keyword>
	<keyword>Bupropion</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Remission</keyword>
	<keyword>Relapse</keyword>
	<keyword>Cost-Effectiveness</keyword>
	<keyword>Atypical Antipsychotic</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Augmentation</keyword>
	<keyword>Veterans</keyword>
	<keyword>Mental Health</keyword>
</DOC>